6533b85afe1ef96bd12b9698
RESEARCH PRODUCT
Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigoleet al
Nona JanikashviliMaxime SamsonBernard BonnotteSylvain Audiasubject
BiopsyGiant Cell ArteritisImmunologyGeneral Biochemistry Genetics and Molecular Biologylaw.inventionRheumatologyRecurrenceConfocal microscopylawBiopsymedicineHumansImmunology and AllergyGlucocorticoidsmedicine.diagnostic_testbusiness.industryInterleukin-17InterleukinFOXP3Forkhead Transcription Factorsmedicine.diseaseInterleukin-10Temporal ArteriesGiant cell arteritisInterleukin 10ImmunologyTh17 CellsInterleukin 17businessGlucocorticoidmedicine.drugdescription
We have read with interest the recently published paper of Espigol-Frigole et al 1 in which the authors confirmed that interleukin (IL)-17 is highly expressed in giant cell arteritis (GCA) lesions.1–3 They also demonstrated for the first time that IL-17 expression in temporal artery biopsies (TABs) was correlated with a better outcome. Among other interesting results, the identification of Foxp3+IL-17+ T cells by confocal microscopy in TAB made the authors to hypothesize that these cells could be induced regulatory T cells (Treg) that may facilitate the remission of the disease under steroid therapy. …
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-03-12 | Annals of the Rheumatic Diseases |